title: Tyrosine kinase inhibitors against EGF receptor-positive malignancies.
authors.affiliation: Parker Hughes Cancer Center and Drug Discovery Program, Parker Hughes Institute, St. Paul, MN, USA.
authors.forename: E A
authors.initials: EA
authors.lastname: Sudbeck
authors.forename: S
authors.initials: S
authors.lastname: Ghosh
authors.forename: X P
authors.initials: XP
authors.lastname: Liu
authors.forename: Y
authors.initials: Y
authors.lastname: Zheng
authors.forename: D E
authors.initials: DE
authors.lastname: Myers
authors.forename: F M
authors.initials: FM
authors.lastname: Uckun
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D000577:Amides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000814:Aniline Compounds / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001943:Breast Neoplasms / Q000473:pathology; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D004815:Epidermal Growth Factor / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000187:drug effects; D005260:Female; D019833:Genistein / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000473:pathology; D008252:Macaca fascicularis; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID; D008958:Models, Molecular; D015394:Molecular Structure; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D009570:Nitriles / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011487:Protein Conformation; D017434:Protein Structure, Tertiary; D011799:Quinazolines / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000037:antagonists & inhibitors; D016415:Sequence Alignment; D013045:Species Specificity; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014410:Tumor Stem Cell Assay; D023041:Xenograft Model Antitumor Assays
chemical_list: D000577:Amides; D000814:Aniline Compounds; D000970:Antineoplastic Agents; C425945:EGF-genistein; D004791:Enzyme Inhibitors; C117143:LFM A12; C118451:LFM A13; D009363:Neoplasm Proteins; D009570:Nitriles; D011799:Quinazolines; D011993:Recombinant Fusion Proteins; C113888:WHI P154; C416931:WHI P97; D004815:Epidermal Growth Factor; D019833:Genistein; D066246:ErbB Receptors